MARC record from Internet Archive

LEADER: 04721cam 2200709 a 4500
001 ocm53123939
003 OCoLC
005 20201007223906.0
008 030923s2004 enka b 001 0 eng
040 $aNLM$beng$cNLM$dUKM$dC#P$dVET$dBAKER$dVAM$dMUQ$dVRC$dYDXCP$dCGC$dBTCTA$dNHTWA$dBDX$dWUM$dOCLCO$dOCLCQ$dOCLCO$dUKRCN$dOCLCF$dOCLCO$dUKMGB$dOCLCA
015 $aGBA3U3796$2bnb
016 7 $a101228182$2DNLM
016 7 $a006959082$2Uk
019 $a61216439$a1191305760
020 $a9781841843698
020 $a1841843695
035 $a(OCoLC)53123939$z(OCoLC)61216439$z(OCoLC)1191305760
042 $anlmcopyc
050 4 $aRC848.H42$bP69 2004
060 00 $a2004 J-822
060 10 $aWC 536$bP892h 2004
082 04 $a616.3623061$221
100 1 $aPoynard, T.$q(Thierry)
245 10 $aHepatitis C and B :$bmanagement and treatment /$cThierry Poynard.
250 $a2nd ed.
260 $aLondon ;$aNew York :$bTaylor & Francis,$c2004.
300 $av, 168 pages :$billustrations ;$c24 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
500 $a"A Martin Dunitz book."
500 $aRevised edition of: Hepatitis B and C. 2002.
504 $aIncludes bibliographical references and index.
505 0 $aNatural history of hepatitis C: epidemiology -- Natural history of hepatitis C: hepatic manifestations -- Natural history of hepatitis C: extrahepatic manifestations and quality of life -- Management protocols in chronic hepatitis C -- Management of relapsers and nonresponders-maintenance therapy -- Management of patients with cirrhosis -- Management of patients coinfected by HCV and HIV -- Management of HCV infection after liver transplantation -- Management of patients with renal disease -- Other difficult-to-treat populations -- Safety of interferon, pegylated interferon (PEG-IFN) and ribavirin -- Who needs to be treated and how to explain the goals to the patient -- What is the cost-effectiveness of combination regimes? -- Management of acute hepatitis C -- Practical guidelines for the management of hepatitis C -- New drugs in development -- Natural history of hepatitis B: Epidemiology -- Natural history of hepatitis B: hepatic manifestations -- Natural history of hepatitis B: extrahepatic manifestations and quality of life -- Goal of treatment in chronic hepatitis B -- Efficacy of interferon and pegylated interferon (PEG-IFN) -- Efficacy of lamivudine -- Comparison between lamivudine, interferon and the combination of interferon and lamivudine -- Safety of lamivudine -- Efficacy of adefovir -- Safety of adefovir -- First-line treatment of chronic hepatitis B: adefovir, lamivudine or interferon? New drugs in development -- Who needs to be treated and how to explain the goals to the patient -- Management of relapsers and nonresponders -- Management of patients coinfected by HBV and HIV -- Management of transplanted patients chronically infected by HBV -- Cost-effectiveness of treatment -- Needle biopsy of the liver: values and limitations -- Advantage and limits of biochemical markers.
520 $aProvides a practical explanation of the natural history and management of the diseases, and examines the benefits of the most recent drugs, and their effects, whether used in isolation or as part of a combination therapy. This second edition expands the coverage of biochemical markers and of the tgreatment of various difficult-to-treat patients.
650 0 $aHepatitis B$xTreatment.
650 0 $aHepatitis C$xTreatment.
650 0 $aInterferon$xTherapeutic use.
650 0 $aBiochemical markers$xTherapeutic use.
650 6 $aHépatite B$xTraitement.
650 6 $aHépatite C$xTraitement.
650 6 $aHépatite virale.
650 7 $aHepatitis C$xTreatment.$2fast$0(OCoLC)fst00955216
650 7 $aInterferon$xTherapeutic use.$2fast$0(OCoLC)fst00976245
650 12 $aHepatitis B, Chronic$xdrug therapy.
650 12 $aHepatitis C, Chronic$xdrug therapy.
650 22 $aHepatitis B, Chronic$xcomplications.
650 22 $aHepatitis C, Chronic$xcomplications.
700 1 $aPoynard, T.$q(Thierry).$tHepatitis B and C.
880 $6020-00$a1841843695 (cased)
938 $aBaker & Taylor$bBKTY$c119.95$d.00$i1841843695$n0004294369$sactive
938 $aBrodart$bBROD$n02084341$c$119.95
938 $aBaker and Taylor$bBTCP$nBK0006725954
938 $aYBP Library Services$bYANK$n100347245
029 0 $aNLM$b101228182
029 1 $aAU@$b000026315938
029 1 $aAU@$b000027966957
029 1 $aNZ1$b9970835
029 1 $aYDXCP$b100347245
029 1 $aUKMGB$b006959082
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 111 OTHER HOLDINGS